Paydirt
TSHA
Ticker

Taysha Gene Therapies, Inc.

TSHA · Healthcare · Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based…

Taysha Gene Therapies, Inc. (TSHA), in the Healthcare sector, has 7 disclosed filings on Paydirt over the trailing twelve months from 3 corporate insiders: 0 purchases and 7 sales. Filers took a median of 3 days from execution to disclosure, and the most recent trade was executed Jul 10 and filed Jul 10. The most active filer was Sukumar Nagendran with 7 filings.

Add to watchlist
Filings, ttm
7
0 buys · 7 sells
Traders, ttm
3
3 insiders
Volume, ttmiDollar value disclosed in the window
$6.7M
estimated for Congress, as filed for insiders
Median delay
3d
execution to disclosure
Last traded
Jul 10
Filed Jul 10
ADViAverage daily dollar volume
$19.6M
market data
Share price · 12M
$5.89 (+105.4%)
$6.98$4.92$2.87Sep 22 2025Mar 5Aug 14

Adjusted for splits and dividends.

Volume by month
$2.8M$1.4M$0Oct 2024Apr 2025Oct 2025Apr 2026Jun 2025 · buys $2.1MAug 2025 · sells $318KSep 2025 · sells $646KDec 2025 · sells $1.7MJan 2026 · sells $2.8MApr 2026 · sells $892KJul 2026 · sells $1.2M
Buys $2.1M Sells $7.6M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed
SN Sukumar Nagendran President and Head of R&D 7 filings KA Kamran Alam CHIEF FINANCIAL OFFICER 2 filings PM Paul B Manning Director 1 filing SN Sean P. Nolan Chief Executive Officer 1 filing
Recent filings
Sukumar NagendranSALE President and Head of R&D $1.2M
200,000 sh × $6.24
Exec Jul 10
Filed Jul 10 · 6:54 PM ET Sukumar NagendranSALE President and Head of R&D $892K
200,000 sh × $4.46
Exec Apr 10
Filed Apr 13 · 5:30 PM ET Kamran AlamSALE CHIEF FINANCIAL OFFICER $485K
102,817 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET Sean P. NolanSALE Chief Executive Officer $840K
178,101 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET Sukumar NagendranSALE President and Head of R&D $547K
116,050 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET Sukumar NagendranSALE President and Head of R&D $942K
200,000 sh × $4.71
Exec Jan 12
Filed Jan 14 · 5:30 PM ET Sukumar NagendranSALE President and Head of R&D $1.7M
370,172 sh across 2 lots
Exec Nov 28 2025
Filed Dec 1 2025 · 5:30 PM ET Sukumar NagendranSALE President and Head of R&D $646K
200,000 sh × $3.23
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET Kamran AlamSALE CHIEF FINANCIAL OFFICER $155K
54,491 sh × $2.85
Exec Aug 21 2025
Filed Aug 22 2025 · 5:30 PM ET Sukumar NagendranSALE President and Head of R&D $163K
57,054 sh × $2.85
Exec Aug 21 2025
Filed Aug 22 2025 · 5:30 PM ET Paul B ManningPURCHASE 10% owner $2.1M
750,000 sh × $2.75
Exec May 30 2025
Filed Jun 3 2025 · 5:30 PM ET